Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843127 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01843127: Completed Phase 1 study, sponsored by Gilead Sciences.
NCT01843127 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01843127, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Ranolazine
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT01843127 record still lists
NCT01843127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01843127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01843127 about?
NCT01843127 is a clinical study titled "A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.". To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01843127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01843127?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT01843127?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01843127's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia